Drugs / Panitumumab-IRDye800
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07493447 | Jul 2026 → May 2030 expected | acoustic neuroma, brain cancer, glioblastoma, meningioma +1 | Eben Rosenthal | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06819228 | Apr 2025 → Mar 2028 expected | head and neck squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05945875 | Oct 2023 → Dec 2027 expected | head and neck squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03733210 | Jan 2019 → Dec 2020 | head and neck squamous cell carcinoma | Andrei Iagaru | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04085887 | Dec 2026 → Dec 2028 expected | brain neoplasm | Stanford University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03582124 | Jul 2018 → Apr 2027 expected | lung carcinoma | Stanford University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03510208 | May 2018 → Nov 2026 expected | brain cancer, malignant glioma | Stanford University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03384238 | Feb 2018 → Mar 2027 expected | pancreatic adenocarcinoma | George Poultsides | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04511078 | Apr 2021 → Dec 2030 expected | head and neck cancer | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT03405142 | Aug → Dec 2019 | head and neck squamous cell carcinoma | Eben Rosenthal | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | panitumumab-IRDye800 | “Panitumumab-IRDye800 (Pan800) or a fluorescently labeled Panitumumab infusion.” NCT06819228 ↗ |
| Known as | Pan800 | “This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing...” NCT07493447 ↗2“Fluorescence-guided imaging of the wound bed was performed with PDE-GEN3 near-infrared (NIR) imaging following infusion of an optically EGFR-targeted antibody,...” PMID 41498537 ↗ Jan 2026 “Panitumumab-IRDye800 (Pan800) or a fluorescently labeled Panitumumab infusion.” NCT06819228 ↗ |
| Modality | Diagnostic / imaging agent | “as an optical imaging agent” NCT03510208 ↗ |
| Route | Intravenous | “patients then receive panitumumab-IRDye800 IV over 60 minutes on day 0” NCT03384238 ↗ |
| Target | EGFR | “anti-epidermal growth factor receptor (EGFR) antibody” NCT04085887 ↗ |